On Wednesday, Deckers Outdoor Corp (NYSE:DECK)’s shares inclined 2.18% to $71.72.
Deckers Outdoor Corp (DECK) will host meetings with investors at the Nomura Securities Retail Conference on Tuesday, June 9, 2015 and the Piper Jaffray 35th Annual Consumer Conference on Wednesday, June 10, 2015.
In addition, Chief Executive Officer and Chair of the Board, Angel Martinez and Chief Financial Officer, Tom George will take part in a fireside chat talk about during the Piper Jaffray Conference at 11:25 am ET on Wednesday, June 10, 2015. A live audio webcast of the fireside chat will be accessible on the Company’s investor relations site at www.deckers.com/investors. An archive of the webcast will be accessible for replay on this website.
Deckers Outdoor Corporation designs, markets, and distributes footwear, apparel, and accessories for outdoor activities and casual lifestyle use for men, women, and children. The company offers luxurious comfort footwear, handbags, apparel, and cold weather accessories under the UGG brand name; sandals, shoes, boots, and amphibious footwear under Teva brand name; and action sport footwear under the Sanuk brand name. It also offers high-end casual footwear under the TSUBO brand name; outdoor performance and lifestyle footwear under the Ahnu brand name; and footwear for culinary professionals under the MOZO brand name, in addition to running footwear under the Hoka One One brand name.
General Dynamics Corporation (NYSE:GD)’s shares gained 0.06% to $140.68.
The board of directors of General Dynamics (GD) disclosed a regular quarterly dividend of 69 cents per share on the company’s common stock, payable August 7, 2015, to shareholders of record on July 3.
General Dynamics is a market leader in business aviation; combat vehicles, weapons systems and munitions; shipbuilding; and communications and information technology systems.
General Dynamics Corporation operates as aerospace and defense company worldwide. It operates through four business groups: Aerospace; Combat Systems; Information Systems and Technology; and Marine Systems. The Aerospace group designs, manufactures, and outfits business-jet aircrafts; provides aircraft services, such as maintenance, repair work, fixed-based operations, and aircraft administration services; and performs aircraft completions for aircraft. The Combat Systems group is involved in the systems engineering, spanning design, development, manufacture, and support of military vehicles, weapons systems, and munitions.
At the end of Wednesday’s trade, Albany Molecular Research, Inc. (NASDAQ:AMRI)‘s shares surged 0.50% to $20.07.
Albany Molecular Research, Inc. (AMRI) declared that it has signed a collaborative agreement with biotechnology company HarkerBIO LLC to co-market their structure-based drug discovery services to global pharmaceutical and biotechnology clients. As part of the three-year agreement, AMRI gains access to HarkerBIO’s uniquely differentiated high-resolution, structure-determination expertise and capabilities. HarkerBIO’s customers will be able to access and benefit from AMRI’s global capabilities, counting their integrated drug discovery platforms and solutions.
Aimed at accelerating decision making and success in the translation from discovery to the clinic, the alliance with HarkerBIO is an early example of the types of partnerships AMRI is creating. AMRI’s new discovery center is co-located on the Buffalo Niagara Medical Campus and is part of the larger commitment by the State of New York.
Albany Molecular Research, Inc., a contract research and manufacturing company, provides integrated drug discovery, development, and manufacturing services primarily in the United States, Europe, and Asia. It operates through three segments: Discovery and Development Services (DDS), API, and Drug Product. The DDS segment offers services from target identification tools to investigational new drug enabling activities, such as diverse chemistry library design and synthesis, medicinal chemistry, biology, and pharmacology, counting drug metabolism and pharmacokinetics.
Ardelyx Inc (NASDAQ:ARDX), ended its Wednesday’s trading session with 39.72% gain, and closed at $14.95.
Ardelyx Inc (ARDX) declared that it has reached a contract to sell shares of its common stock and warrants to purchase shares of common stock for aggregate gross proceeds of about $77.8 million in a private placement. New Enterprise Associates (NEA), the Company’s largest shareholder and one of the largest biotechnology investors worldwide, has committed to invest about $50.2 million in the private placement and a combination of new and existing investors, counting RA Capital Administration, Broadfin Capital LLC, Cormorant Asset Administration LLC, Foresite Capital Administration, LLC, Rock Springs Capital Administration LP, and a fund managed by Sabby Capital, LLC, have committed to invest the remaining $27.6 million. Additionally, Ardelyx declared a new program, RDX022, a non-absorbed polymer, for the treatment of hyperkalemia.
Ardelyx, Inc. discovers, develops, and commercializes minimally-systemic small molecule therapeutics for the gastrointestinal (GI) tract to treat cardio-renal, GI, and metabolic diseases. Its lead product candidate is tenapanor, a small molecule NHE3 inhibitor, which has accomplished Phase 2b clinical trial for the treatment of patients with constipation-predominant irritable bowel syndrome and hyperphosphatemic patients with chronic kidney disease on dialysis, in addition to Phase 2a clinical trial in patients with late-stage chronic kidney disease.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
